D&A
McKesson D&A increased by 17.0% to $62.00M in Q2 2025 compared to the prior quarter. Year-over-year, this metric declined by 1.6%, from $63.00M to $62.00M. Over 3 years (FY 2022 to FY 2025), D&A shows a downward trend with a -4.6% CAGR.
Analysis
How to read this metric
Higher levels indicate significant capital investment in infrastructure or acquisitions, while lower levels may suggest aging assets or limited capital expenditure.
Detailed definition
This represents the non-cash expense allocated to the cost of tangible and intangible assets over their useful lives. Be...
Peer comparison
High in capital-intensive industries like manufacturing and healthcare devices; lower in service-based sectors.
depreciation_and_amortization_cfHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $80.00M | $44.00M | $61.00M | $94.00M | $61.00M | $68.00M | $62.00M | $57.00M | $64.00M | $60.00M | $58.00M | $71.00M | $63.00M | $61.00M | $65.00M | $53.00M | $62.00M |
| QoQ Change | — | -45.0% | +38.6% | +54.1% | -35.1% | +11.5% | -8.8% | -8.1% | +12.3% | -6.3% | -3.3% | +22.4% | -11.3% | -3.2% | +6.6% | -18.5% | +17.0% |
| YoY Change | — | — | — | — | -23.8% | +54.5% | +1.6% | -39.4% | +4.9% | -11.8% | -6.5% | +24.6% | -1.6% | +1.7% | +12.1% | -25.4% | -1.6% |
Business Segments
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | Q4 '26 |
|---|---|---|---|---|---|---|---|---|
| Medical-Surgical Solutions | $23.00M | $22.00M | $23.00M | $24.00M | $22.00M | $23.00M | $26.00M | $25.00M |
| Prescription Technology Solutions | $21.00M | $22.00M | $22.00M | $21.00M | $21.00M | $20.00M | $21.00M | $20.00M |
| International | $30.00M | — | — | — | $14.00M | — | — | — |
| U.S. Pharmaceutical | $60.00M | — | — | — | $63.00M | — | — | — |
| Total | $63.00M | $61.00M | $65.00M | $53.00M | $62.00M | — | — | — |
International, U.S. Pharmaceutical were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.
D&A at Other Companies
Frequently Asked Questions
- What is McKesson's d&a?
- McKesson (MCK) reported d&a of $62.00M in Q2 2025.
- How has McKesson's d&a changed year-over-year?
- McKesson's d&a decreased by 1.6% year-over-year, from $63.00M to $62.00M.
- What is the long-term trend for McKesson's d&a?
- Over 3 years (2022 to 2025), McKesson's d&a has grown at a -4.6% compound annual growth rate (CAGR), from $279.00M to $242.00M.
- What does d&a mean?
- The non-cash accounting expense for the wear and tear or expiration of assets.